Bicara Therapeutics (NASDAQ:BCAX) CEO Claire Mazumdar Sells 36,766 Shares

Bicara Therapeutics Inc. (NASDAQ:BCAX) CEO Claire Mazumdar sold 36,766 shares of the business’s stock in a transaction dated Monday, March 9th. The shares were sold at an average price of $19.17, for a total value of $704,804.22. Following the sale, the chief executive officer directly owned 339,392 shares of the company’s stock, valued at approximately $6,506,144.64. This trade represents a 9.77% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Claire Mazumdar also recently made the following trade(s):

• On Friday, March 6th, Claire Mazumdar sold 3,817 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.75, for a total value of $71,568.75.
• On Wednesday, March 4th, Claire Mazumdar sold 2,631 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.73, for a total value of $49,278.63.
• On Thursday, March 5th, Claire Mazumdar sold 1,786 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.74, for a total transaction of $33,469.64.

Bicara Therapeutics Price Performance

NASDAQ:BCAX traded down $0.13 during mid-day trading on Thursday, reaching $19.77. The stock had a trading volume of 13,459 shares, compared to its average volume of 500,445. Bicara Therapeutics Inc. has a 1-year low of $7.80 and a 1-year high of $20.25. The company has a market capitalization of $1.08 billion, a price-to-earnings ratio of -8.76 and a beta of -0.78. The stock’s 50 day simple moving average is $16.67 and its two-hundred day simple moving average is $15.96.

Institutional Trading of Bicara Therapeutics

Large investors have recently modified their holdings of the company. Legal & General Group Plc lifted its position in Bicara Therapeutics by 64.1% during the 2nd quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock worth $29,000 after acquiring an additional 1,233 shares during the last quarter. Ameritas Investment Partners Inc. lifted its holdings in shares of Bicara Therapeutics by 73.0% during the second quarter. Ameritas Investment Partners Inc. now owns 3,493 shares of the company’s stock worth $32,000 after buying an additional 1,474 shares during the last quarter. Tower Research Capital LLC TRC increased its position in Bicara Therapeutics by 419.3% during the second quarter. Tower Research Capital LLC TRC now owns 4,788 shares of the company’s stock worth $44,000 after acquiring an additional 3,866 shares during the period. Mirae Asset Global Investments Co. Ltd. acquired a new position in Bicara Therapeutics during the 4th quarter valued at $45,000. Finally, Larson Financial Group LLC raised its stake in Bicara Therapeutics by 1,015.5% during the 3rd quarter. Larson Financial Group LLC now owns 3,949 shares of the company’s stock valued at $62,000 after purchasing an additional 3,595 shares during the last quarter.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on BCAX. Wedbush reissued an “outperform” rating and set a $30.00 price objective on shares of Bicara Therapeutics in a research note on Tuesday, January 13th. Mizuho upgraded Bicara Therapeutics to a “hold” rating in a report on Thursday, December 18th. Citizens Jmp initiated coverage on shares of Bicara Therapeutics in a research note on Thursday, January 29th. They set a “market perform” rating and a $31.00 price objective for the company. Citigroup assumed coverage on shares of Bicara Therapeutics in a report on Thursday, January 29th. They issued an “outperform” rating for the company. Finally, UBS Group restated a “buy” rating on shares of Bicara Therapeutics in a research report on Wednesday, January 14th. Seven equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $28.33.

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.